Relugolix

Overview

Relugolix is an orally-active non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of hormone-sensitive conditions such as prostate cancer and uterine fibroids. It works by reducing the levels of certain hormones in the body, thus inhibiting tumor growth in hormone-dependent cancers.

API suppliers (17)

Suppliers of Relugolix evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• DR REDDYS LABORATORIES LTD1 active DMF GMP on record
• LEE PHARMA LTDIndia1 active DMF GMP on record
• BEIJING HOPE PHARMACEUTICAL CO LTD1 active DMF
• MOEHS IBERICA SLSpain1 active DMF GMP on record
• Aurisco Pharmaceutical Co.,ltdChina1 active DMF GMP on record
• CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
• Cipla USA, Inc.USA1 active DMF
• Porton Pharma Solutions Ltd.China1 active DMF
• BDR LIFESCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
• Biocon LimitedIndia1 active DMF
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
• WEINAN MANARECO PHARMACEUTICAL CO LTD1 active DMF
• Jiangsu Lianhuan Pharmaceutical Co.,Ltd.China1 active DMF
• Zhejiang Jingsheng Pharmaceutical Co., Ltd.China1 active DMF
• Shandong Loncom Pharmaceutical Co.,ltd.China1 active DMF
• Intas Pharmaceuticals Ltd.India GMP on record

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Relugolix expires 29 Sept 2037. Generic API sourcing typically opens up once these lapse.

Therapeutic areas